Background-Calcific aortic valve stenosis (AS) is a major societal and economic burden that is rising after the current shift toward an older population. Understanding the pathobiology of AS is crucial to implementing better preventive and therapeutic options. Research conducted during the past decade clearly points to active molecular and cellular processes involved in disease pathogenesis. However, no genomic approaches were used to identify genes and pathways that are differentially regulated in aortic valves of patients with and without AS. Methods and Results-A large-scale quantitative measurements of gene expression was performed on 5 normal and 5 AS valves using Affymetrix GeneChips. A total of 409 and 306 genes were significantly up-and downregulated in AS valves, respectively. The 2 most highly upregulated genes were matrix metalloproteinase 12 and chitinase 3-like 1. The upregulation of these 2 biologically relevant genes in AS was validated by real-time polymerase chain reaction in 38 aortic valves (12 normal and 26 AS). To provide a global biological validation of the whole-genome gene expression analysis, the microarray experiment was repeated in a second set of aortic valves with (nϭ5) or without (nϭ5) AS. There was an overrepresentation of small P values among genes claimed significant in the first microarray experiment. A total of 223 genes were replicated (PϽ0.05 and fold change Ͼ1.2), including matrix metalloproteinase 12 and chitinase 3-like 1. Conclusions-This study reveals many unrecognized genes potentially implicated in the pathogenesis of AS. These new genes were overlaid on known pathological pathways leading to AS to refine our molecular understanding of this disease. (Circ Cardiovasc Genet. 2009;2:489-498.)
C alcific aortic valve disease is a growing health problem with important clinical consequences. 1 The condition is initiated with focal subendothelial lesions on the aortic side of the leaflet, similar to atherosclerosis plaques, which eventually progress to aortic stenosis (AS). Histopathologically, AS is characterized by massive calcification and fibrous thickening of the valve cusps leading to left ventricular outflow tract obstruction. 2, 3 Patients with AS have an 80% risk of valve replacement, progression to heart failure, or death in the next 5 years after diagnosis. 4 A rapid increase in the incidence of hospitalization because of AS was noticed during the past decades. 1 In the same timeframe, there was also a marked increase in the number of aortic valve replacement procedures. The cost associated with these surgical procedures is very high. 5 In addition, as the prevalence of the disease increases markedly with age, 6 the population at risk rises in proportion to the improvement in life expectancy. Accord-ingly, AS is now a major societal and economic burden that is likely to be substantiated in a near future. It is thus an urgent priority to understand the pathobiological processes leading to AS at the most fundamental level to improve preventive and therapeutic strategies.
Clinical Perspective on p 498
Molecular studies conducted during the past decade provided evidences that support the implication of active molecular and cellular processes in the pathogenesis of AS. These include genes involved in subendothelial deposition and retention of atherogenic lipoproteins, chronic inflammation, the renin-angiotensin system, remodeling, fibrosis, and neovascularization, as well as specific cell-signaling pathways regulating nitric oxide and ectopic calcification. 7, 8 Accordingly, the number of genes potentially involved in pathological pathways leading to AS is vast. Genomic approaches offer a solution to overcome this level of complexity and have not yet been used to explore AS pathobiology. 9 In this study, we adopt a genomic approach that allows us to test the expression of most of the known genes simultaneously in aortic valves of patients with or without AS. The created data set constitutes the most complete picture of genes that are perturbed in AS. The results confirm, refine, and comprehensively complement biological processes that are known to be involved in AS. It also identified novel genes and pathways that provide new promising targets for the treatment of AS.
Methods

Aortic Valves
Two independent microarray experiments were performed. Each experiment involved 5 AS valves and 5 normal aortic valves. Table  1 shows the characteristics of the 20 patients from whom the valve was explanted for microarray application. To reduce heterogeneity, only valves taken from white male subjects were selected. Stenotic and control valves were also matched for age and body mass index of the patients. Patients were paired for age if they were within 5 years of age or if they were both younger than 50. Patients were paired for body mass index if they were within 5 kg/m 2 . For the second microarray experiment, patients were specifically selected as nonsmokers without type II diabetes or renal insufficiency (defined with creatinine levels Ͼ150 mol/L). Patients were also matched for statin treatment and hypertension. It should be noted that subjects were paired for clinical characteristics within each case-control set, but no attempts were made to match patients between the 2 microarray experiments because of the limited number of control valves. All valves were stored at Ϫ80°C in a local biobank before RNA extraction.
AS valves were collected from patients with severe AS undergoing aortic valve replacement at the Institut Universitaire de Cardiologie et de Pneumologie de Québec. Only patients with tricuspid nonrheumatic AS were eligible for this study. The AS valves analyzed in this study were selected to have the same degree of fibro-calcific remodeling based on a modified version of the scoring system proposed by Warren and Yong. 10 This score is determined by the extent of fibro-calcific remodeling of the valvular tissue and ranges from 1 to 4. Only valves classified as grade 3 were selected in this study. Grade 3 valves are characterized by gross thickening and distortion with many calcified nodules and a distorted fibrosa. AVR indicates aortic valve replacement. *These samples failed QC and were eliminated from the analyses.
Normal noncalcified aortic valves were collected from hearts harvested at the time of cardiac transplantation (nϭ9) or aortic replacement (nϭ1; patient having a replacement of the aortic root owing to an aneurysm of the ascending aorta; Table 1 ). Hearts explanted from patients having a history of valvular heart diseases (at any of the 4 valves) or having evidence of valvular heart disease at macroscopic or microscopic evaluation were excluded from this control group. All the aortic valves included in the control group had a preoperative valve area Ͼ2 cm 2 , no evidence of significant regurgitation (grade Ͼ2) and no morphological abnormalities at postexplant examination. All tissues were obtained from the local biobank. A written informed consent to participate in genetic studies is obtained from all individual contributing to the biobank.
RNA Extraction
RNA was extracted using the RNeasy Lipid Tissue Kit (QIAGEN, Mississauga, Ontario). The RNA extraction protocol was performed according to manufacturer's instructions using 100 mg of tissue. RNA quality was assessed using the Agilent 2100 Bioanalyzer (online-only Data Supplement).
Micorarrays
Expression studies were performed using the human U133 plus 2.0 Affymetrix GeneChip microarrays (Affymetrix, Santa Clara, Calif). Arrays were process using a standard Affymetrix double amplification protocol using 80 ng of RNA. More technical details are provided in the online-only Data Supplement. Expression values were extracted using the Robust Multichip Average (RMA) method. 11 Quality control assessment was performed with the FlexArray software version RC3 and the affy package that is part of the Bioconductor project (http://www.bioconductor.org/).
After RMA normalization, the mean and distribution of expression values was comparable among arrays for the 2 microarray data sets (supplemental Figure IA and IB). Principal component analyses were then conducted using Cluster 3.0 to visualize the overall pattern of gene expression between aortic stenotic and normal valves. Figure 1 shows the principal component analyses results. For the first microarray experiment, the gene expression profile of aortic stenotic valves cluster tightly on the principal component analyses plot ( Figure 1A ). On the other hand, the gene expression profile of 2 normal valves was considerably away from the remaining samples. The most extreme gene expression profile was derived from the sample with low-RNA integrity score (VAHN9). Accordingly, this array was removed from further analyses. Additional quality controls were performed to understand the shift in expression profile for the second most extreme sample (VAHN31). The raw images intensity revealed an irregularity in the array and was, therefore, also removed from subsequent analyses (supplemental Figure II) . Hence, for the first microarray experiment, the comparison of gene expression was performed between 5 AS and 3 normal valves. For the second microarray experiment, the gene expression profile of 1 normal valve (VAHN69) was considerably different ( Figure 1B ). This gene expression profile was derived from the sample with the lowest RNA integrity score and was excluded from the analysis. Therefore, for the second microarray experiment, the comparison of gene expression was performed between 5 AS and 4 normal valves.
Significant Analysis of Microarrays method was used to claim significant regulation in the first microarray experiment. 12 The minimum fold change and the ␦ values was set to 2 and 0.76, respectively, to reach a false discovery rate below 5% (4.85%). Only significant probe sets (nϭ1002) were considered and tested in the second microarray experiment, which aim at providing a global biological validation of genes claim significant in the first microarray data set. Probe sets (genes) were tested using a 1-tailed Student t test. Replication was confirmed for probe sets with a PϽ0.05 and a fold change of at least 1.2.
The complete data set, including the first and second microarray experiments, has been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (http://www. ncbi.nlm.nih.gov/geo) repository and are accessible through Gene Expression Omnibus Series accession number GSE12644.
Real-Time PCR
Real-time polymerase chain reaction (PCR) was used for 2 purposes. First, to provide technical validation of the first microarray experiment using a method recently described by Miron et al. 13 The method consists of validating a subset of randomly selected genes by real-time PCR using the same RNAs used on the microarrays and extrapolating the results to the remaining nonvalidated genes. More specifically, the 409 upregulated genes in the first microarray experiment were sorted by descending order of fold change. Gene selection was then performed using a random-stratified sampling method using a bin size of 25 (we randomly select 1 gene per bin for the top 200 upregulated genes). As a result, the following 8 genes were selected and tested by real-time PCR: LRRC15, IGKC, GZMA, BGN, KIT, CTHRC1, FAM7A1, and CR1L. The CR1L gene was excluded from the analysis because the real-time PCR assay failed. Amplification efficiencies were validated and normalized to 18S gene and quantity of target gene were calculated according to the comparative C T method. A concordant correlation coefficient was then estimated for the remaining 7 genes to evaluate the similarity between microarray and real-time PCR results. The concordant correlation coefficient is a global quality index combining the accuracy and precision coefficients in 1 index. 13 Second, real-time PCR was used to provide biological validation for the 2 most highly upregulated genes in the first microarray data set (matrix metallo- Table 1 .
proteinase [MMP] 12 and chitinase 3-like 1 [CHI3L1]
). Thirty-eight additional aortic valves were used for this experiment (12 normal and 26 AS valves). The analyses were calibrated according to the standard curve method and normalized with the hypoxantine phosphoribosyltransferase reference gene. Technical details for real-time PCR can be found in the Data Supplement.
Biological Pathway
The Ingenuity Pathway Analysis system (Ingenuity Systems, www.ingenuity.com) was used to visualize gene expression data in the context of biological pathways. Methods and Results are presented in the Data Supplement.
Results
Microarray Results
Expression profiling was conducted with Affymetrix Gene-Chip microarrays to identify genes differentially regulated between healthy and calcific aortic valves. Figure 2 shows the fold change versus intensity plot for the 54 675 probe sets present on the array. A total of 1002 probe sets were considered differentially expressed based on a false discovery rate Ͻ5%. The Significant Analysis of Microarrays output listing all the significant probe sets is available in supplemental Table I . These 1002 probe sets correspond to 409 unique genes that are upregulated and 306 unique genes that are downregulated in aortic stenotic valves compared with nonstenotic valves. The 10 most upregulated and 10 most downregulated genes are shown in Table 2 . Interestingly, 3 MMPs were among the top 10 most upregulated genes. Based on this result, a more in-depth investigation of MMPs and their endogenous inhibitors was undertaken. A total of 46 probe sets evaluating 25 different MMPs, and 12 probe sets evaluating 4 tissue inhibitors of metalloproteinases (TIMPs) are available in the data set. Figure 3 shows a heat map illustrating the normalized expression values for each sample for relevant MMPs and all TIMPs. Globally, MMPs are upregulated in aortic valves of patients with AS compared with normal. However, only MMP1, 7, 9, and 12 reached the level of significance. Other MMPs not illustrated in Figure 3 were evaluated and belong to one of the following 2 groups: (1) absent from both the AS and the control valves (MMP-8, -10, -17, -20, - 21, -26, and -27) and (2) present at a similar level between the two groups (MMP-16, -19, -24, and -28).
Global Technical Validation
The first microarray experiment was validated using a methodology described by Miron et al 13 (Methods). Figure 4 summarizes these results. A concordant correlation coefficient value of 0.67 was observed for the present experiment, which indicates good agreement between microarray and real-time PCR results. This result can be visualized by how close the data points are from the regression line (correlation, 0.77) and the direction similarity between the regression line and the identity line.
Validation of 2 Candidate Genes
MMP12 and CHI3L1 were the 2 most highly upregulated genes in the microarray data set ( Table 2 ). These 2 genes were validated by real-time PCR based on their high level of regulation and their potential effect in the pathogenesis of AS. First, they were validated on the technical level using the same tissue RNA samples analyzed in the microarray data set. Figure 5A illustrates the expression values obtained by real-time PCR for MMP12 and CHI3L1 in the 3 normal and 5 stenotic aortic valves. For both genes, the expression values were always higher in stenotic valves compared with normal. These results are in agreement with the microarray findings and confirm again the great concordance between microarray and real-time PCR results. Second, the expression of these 2 genes was validated by real-time PCR on 38 additional aortic valves. Figure 5B illustrates the mean expression values of 12 normal and 26 AS valves. The mRNA expression values of MMP12 and CHI3L1 were significantly higher in AS valves compared with normal. These results clearly demonstrated that the expression of MMP12 and CHI3L1 is upregulated in AS.
Global Biological Validation
To provide a global biological validation of the first wholegenome gene expression analysis, the microarray experiment was repeated in a second set of aortic valves with or without AS. Figure 6 shows the distribution of P values in the second microarray experiment for the 1002 significant probe sets in the first microarray experiment. There is a clear overrepresentation of small P values among genes claim significant in the first microarray experiment. A total of 289 probe sets were replicated (PϽ0.05 and fold change Ͼ1.2). These 289 probe sets correspond to 124 unique genes that are upregulated and 99 unique genes that are downregulated in aortic stenotic valves compared with nonstenotic valves. The list of replicated probe sets with annotation, RMA expression values, and summary statistics are found in supplemental Table II .
Discussion
Many genes and pathways are anticipated to play a role in the pathogenesis of AS. Previous molecular studies have provided a solid framework to study the pathobiological processes leading to AS. 2, 3, 14 Together, these studies have convincingly demonstrated that AS is not the result of a passive degenerative process, but rather a complex pathobiological disorder. They also provide a strong impetus to conduct this study that aims at refining known biological pathways and identifying novel ones involved in AS. To achieve that goal, we explored gene expression profile of human aortic valves in patients with or without AS. The data set that we generated constitutes, to our knowledge, the first large-scale quantitative measurements of gene expression in normal and stenotic human valves. By comparing the gene expression levels of the 2 groups, we identified a list of 715 genes that are up-or downregulated in AS. A large fraction of these genes were biologically replicated in a second microarray experiment. The most highly regulated genes, namely MMP12 and CHI3L1, were validated in biological replicates and constitute new targets to understand the pathogenesis of AS.
Interpretation of Microarray Data Set
Extracting biological information from microarray data are a major challenge. The amount of information is often overwhelming and difficult to interpret. To facilitate the interpretation, we overlaid differentially regulated genes on known pathological pathways that lead to AS (Figure 7) . The colors indicate whether the expression of the genes is upregulated (red), downregulated (blue), or unchanged (white) in AS compared with control valves based on our first microarray data set. A large fraction of these genes were never described in the literature as being dysregulated in AS and provided new knowledge on the pathobiology of this disease. Supplemental Figure III describes in greater detail the genes derived from the literature and microarray data set. The following describes some of the most relevant findings.
Pathophysiological Integration of the Most Highly Upregulated Genes in Aortic Stenosis
The most highly upregulated gene of the data set was MMP12. The role of MMP12 in AS was not considered in previous literature, but the high level of regulation observed in this study suggests that it must be seriously examined. MMP12 is characterized by macrophage-specific expression and is known to degrade elastin, the main component of elastic fibers. 15 Macrophages derived from MMP12-deficient mice have a markedly diminished capacity to degrade extracellular matrix and are unable to penetrate basement membrane in vitro and in vivo. 16 Interestingly, these mice, in contrast to the wild-type, did not develop emphysema in response to long-term exposure to cigarette smoke. 17 In AS, the elastolytic activity of MMP12 may degrades elastin and participates actively to the remodeling of extracellular matrix, which is incidentally related to the aortic gradient. 18 The second most highly regulated gene was CHI3L1, also named YKL-40 or cartilage glycoprotein-39. This gene plays a role in remodeling of the extracellular matrix. 19 -22 CHI3L1 is known to induce proliferation of chondrocytes and stimulate proteo- glycan synthesis from these cells in a dose-dependent manner. 20 Interestingly, the chondrocyte mitogenic activity of CHI3L1 seems to be mediated by SOX9, 21 which is a transcription factors for osteoblast differentiation that was shown to be upregulated in human degenerative valve. 23 Finally, the third most highly upregulated gene was the integrin-binding sialoprotein, which was previously shown to be upregulated in calcified aortic valves. 23, 24 Figure 7 summarized additional refinements to known pathways that were allowed by this experiment. Thus, this study underlines the need to integrate novel findings of genomic approaches to already known pathways and emphasize the power of this tool to expand the scope of our molecular understanding of this disease. For instance, among the top 3 upregulated genes documented in our first microarray experiment, 2 (MMP12 and CHI3L1) were documented for the first time in AS.
MMPs and TIMPs
Tissue remodeling of the extracellular matrix is a key pathophysiological feature of AS. [25] [26] [27] [28] [29] [30] [31] With the current data set, we were able to evaluate the presence or absence of mRNA transcript for a total of 23 different MMPs and 4 TIMPs in control and AS valves as well as to compare the expression levels between the 2 groups. Many MMPs were upregulated in AS (Figure 3 ). However, in addition to MMP12, only 3 of them reach the stringent microarray significance level, including MMP-1, -7, and -9. Concerning the inhibitors, TIMP-1 and -2 seem to be elevated in AS valves compared to control (Figure 3 ). In contrast, TIMP-3 and -4 were downregulated in AS, but only TIMP-4 reach the level of significance. Heterogeneity in expression pattern is also apparent for transcript encoding TIMPs. For example, the expression level of TIMP-3 and -4 for 1 AS valve (VAHC79) is more closely similar to the control valves compared with the other stenotic valves. This heterogeneity may explain some of the controversies regarding the regulation of TIMPs in AS. 28, 30, 31 Clinical Implication
Overall, this study provides a more comprehensive understanding of the molecular pathways leading to AS. This new knowledge may open new avenues of research for the development of effective therapies to stop or reduce the progression of AS. Many Food Drug Administrationapproved drugs are known to act on the gene products involved in pathological pathways leading to AS (supplemental Figure IIID ). However, intensive investigations including animal experiments in recently developed models of AS [32] [33] [34] as well as large clinical studies will be required to demonstrate whether at least one of these drugs or a combination of them is effective to modify the mechanisms leading to calcific AS. In a foreseeable future, refining our molecular understanding of the disease may offer great promise to develop new drugs acting on novel gene targets.
Limitations
Many top up-and downregulated genes are difficult to insert into our current understanding of molecular pathways leading to AS. This is, in large part, due to the lack of knowledge on some of these genes. However, others are likely to act in pathological pathways that were not anticipated so far and provide new leads that require additional investigations. On the other hand, it is also anticipated that a list of significantly regulated genes will be far downstream than their root cause and are likely to be irrelevant to understand the pathogenesis of AS. In fact, our microarray experiment provides only a snapshot of gene expression profile for "healthy" and latestage stenotic aortic valves. Hence, these experiments do not necessarily identify the genes that are up-or downregulated during the initiation and progression of AS. A larger scale microarray experiment including different stages of AS severity is warranted to provide a better appreciation of changes in gene expression profile throughout the progression of the disease. In this study, we used a bioinformatics tool containing knowledge-based information and data derived from the scientific literature to generate biological insights. These approaches were taken to facilitate the interpretation of the large amount of data produced by the microarray technology. However, identification of a functional pathway in this study does not prove its implication and must be confirmed by other studies. It should also be noted that the source of data coming from the mRNA transcript level may not reflect the protein and the cellular functions. Despite these limitations, the data set generates many new leads that required additional investigations. Sharing the large data set and the pathway analyses exploration with the scientific community is likely to generate new ideas and accelerate the confirmation of preventive or therapeutic targets. In the first microarray experiment, we have provided a list of genes that are differentially expressed in aortic stenotic valves. It should be emphasized that false positives are expected and true positives are certainly missing from this list. In an attempt to consolidate this list of genes, we have tested the same genes in a second group of valves taken from patients with or without AS. The overrepresentation of small P values observed in the second set ( Figure 6 ) clearly demonstrated that a large number of genes claim significant in the first microarray experiment are truly differentially expressed between healthy and stenotic valves. This observation is intriguing given that AS is a heterogeneous disease and that the sample size is small in both microarray experiments. Although a large number of genes are replicated, the effect sizes estimated by the microarray platform are substantially different between the 2 experiments. For example, the fold changes for MMP12 and CHI3L1 were 39.7 and 35.2, respectively, in the first set compared with 3.5 and 1.5, respectively, in the second set. A combination of factors may explain these differences including random sampling and measurements errors as well as the inherent limitation of microarrays to quantify gene expression. In this study, the upregulation of MMP12 and CHI3L1 in aortic stenotic valves was robustly confirmed by quantitative real-time PCR in a large sample of aortic valves with or without AS. Similar experiments will be required to confirm all other genes claimed significant in the microarray data sets and to accurately measure their effect size. In the meantime, this whole-genome profiling experiment provide useful infor-mation to refine our understanding of molecular pathways leading to AS and generate new data-driven hypotheses.
Conclusion
We have provided the first gene expression profile of human aortic valves in normal and stenotic states. We also demonstrated that the expression of many genes are regulated in stenotic valves, including genes previously implicated in the pathogenesis of AS. Many more genes than previously anticipated were also involved in known biological processes playing a role in AS such as calcification, inflammation, and remodeling. Overlaying these new genes on known pathways allows us to substantially refine our molecular understanding of the disease. Further studies are required to validate the importance of these genes and biological pathways in AS.
